2018
DOI: 10.3897/rrpharmacology.4.30329
|View full text |Cite
|
Sign up to set email alerts
|

2-phenyl-1-(3-pyrrolidin-1-il-propyl)-1H-indole hydrochloride (SS-68): Antiarrhythmic and Cardioprotective Activity and Its Molecular Mechanisms of Action (Part II)

Abstract: Introduction. In previous studies on different animal models, it was shown that compound N-(N-butylpyrrolidine)-2-phenylindole hydrochloride (SS-68) has a broad antiarrhythmic activity. The molecular mechanisms of the pharmacological action of SS-68 were chosen as the focus for this study. Materials and methods. The study of the molecular basis of the pharmacological action of SS-68 was based on 1) molecular docking with the determination of the affinity constant for κ1-opioid receptors; 2) recording… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 17 publications
0
1
0
Order By: Relevance
“…At the same time, none of the proposed methods and their combinations provide guaranteed protection against ischemia-reperfusion injury, in connection with which the search and selection of innovative and promising compounds and preparations of this orientation continue. Preclinical studies at the systemic (Korokin et al, 2014;Peresypkina et al, 2016;Yakushev et al, 2016), cellular (Danilenko et al, 2016;Kravchenko et al, 2016;Kalmikov et al, 2018), and molecular (Bogus et al, 2018;Dzhimak et al, 2018;Soldativ et al, 2018) levels, including specific activity (Gumanova et al, 2007;Denisyuk et al, 2016;Danilenko, 2018) and toxicology studies (Kolesnichenko et al, 2018) in conjunction with bioequivalence studies )Kalmikov et al, 2018(, therapeutic equivalence and effectiveness (Avdeeva et al, 2016) are an integral part of the research of innovative drugs.…”
Section: Introductionmentioning
confidence: 99%
“…At the same time, none of the proposed methods and their combinations provide guaranteed protection against ischemia-reperfusion injury, in connection with which the search and selection of innovative and promising compounds and preparations of this orientation continue. Preclinical studies at the systemic (Korokin et al, 2014;Peresypkina et al, 2016;Yakushev et al, 2016), cellular (Danilenko et al, 2016;Kravchenko et al, 2016;Kalmikov et al, 2018), and molecular (Bogus et al, 2018;Dzhimak et al, 2018;Soldativ et al, 2018) levels, including specific activity (Gumanova et al, 2007;Denisyuk et al, 2016;Danilenko, 2018) and toxicology studies (Kolesnichenko et al, 2018) in conjunction with bioequivalence studies )Kalmikov et al, 2018(, therapeutic equivalence and effectiveness (Avdeeva et al, 2016) are an integral part of the research of innovative drugs.…”
Section: Introductionmentioning
confidence: 99%